ANYGEN CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,120 KRW | -1.37% |
|
+5.44% | +2.86% |
| 04-05 | Anygen Co., Ltd. announced that it has received KRW 999.98709 million in funding | CI |
| 03-28 | Anygen Co., Ltd. announced that it expects to receive KRW 999.98709 million in funding | CI |
| Sales 2022 | 8.66B 6.3M 8.64M | Sales 2023 | 5.61B 4.08M 5.6M | Capitalization | 87.28B 63.45M 87.1M |
|---|---|---|---|---|---|
| Net income 2022 | -6.2B -4.51M -6.19M | Net income 2023 | -9.08B -6.6M -9.06M | EV / Sales 2022 | 5.6 x |
| Net Debt 2022 | 6.95B 5.06M 6.94M | Net Debt 2023 | 6.33B 4.61M 6.32M | EV / Sales 2023 | 16.7 x |
| P/E ratio 2022 |
-6.69
x | P/E ratio 2023 |
-9.22
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.73% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.37% | ||
| 1 week | +5.44% | ||
| Current month | -9.84% | ||
| 1 month | -9.84% | ||
| 3 months | -14.58% | ||
| 6 months | +8.78% | ||
| Current year | +2.86% |
1 week
13 940.00
15 500.00
1 month
13 240.0016 960.00
Current year
13 240.0019 000.00
1 year
12 380.0023 650.00
3 years
6 510.0030 550.00
5 years
4 715.0030 550.00
10 years
4 715.0037 550.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Il Kim
CEO | Chief Executive Officer | 64 | 00-04-30 |
Chang-Hwan Kim
SAM | Sales & Marketing | 64 | 18-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Il Kim
CEO | Chief Executive Officer | 64 | 00-04-30 |
Young-Joon Kim
BRD | Director/Board Member | 51 | 17-02-28 |
Ji-Yong Park
BRD | Director/Board Member | 56 | 17-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 15,120 | -1.37% | 32,977 |
| 24-04-29 | 15,330 | +0.13% | 21,956 |
| 24-04-26 | 15,310 | +3.03% | 27,289 |
| 24-04-25 | 14,860 | +4.43% | 25,700 |
| 24-04-24 | 14,230 | -0.84% | 19,735 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
ANYGEN CO., LTD. is a Korea-based company mainly engaged in manufacture and distribution of peptides. The Company's products mainly consist of leuprorelin acetate, desmopressin acetate, and contract manufacturing organization (CMO) peptides, which are used for pharmaceuticals; custom peptides, which is used for research, and argireline, which is used for cosmetics. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.86% | 65.6M | |
| +33.25% | 699B | |
| +28.94% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +15.04% | 236B | |
| +4.94% | 198B | |
| -10.59% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- A196300 Stock
